The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention.
about
Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependenceSecondary prevention of HIV infection: the current state of prevention for positivesPersistence of low drug treatment coverage for injection drug users in large US metropolitan areasTreatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.Neurocognitive impairment and HIV risk factors: a reciprocal relationship.Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.Challenges to implementing opioid substitution therapy in Ukrainian prisons: Personnel attitudes toward addiction, treatment, and people with HIV/AIDS.Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centersHepatitis infection in the treatment of opioid dependence and abuse.Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS)HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation.Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity.Clinical care of the HIV-infected drug userBehavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence.Nurse practitioner and physician assistant interest in prescribing buprenorphine.Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes.In Their Own Voices: Breaking the Vicious Cycle of Addiction, Treatment and Criminal Justice Among People who Inject Drugs in Ukraine.Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trialIntegration and co-location of HIV/AIDS, tuberculosis and drug treatment services.Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenanceIntegration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine.Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxoneRetention in medication-assisted treatment programs in Ukraine-Identifying factors contributing to a continuing HIV epidemic.Willingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.Intersecting epidemics of HIV, HCV, and syphilis among soon-to-be released prisoners in Kyrgyzstan: Implications for prevention and treatment.Self-management of buprenorphine/naloxone among online discussion board users.Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening.Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.Opiate Drugs with Abuse Liability Hijack the Endogenous Opioid System to Disrupt Neuronal and Glial Maturation in the Central Nervous System.Change and variability in drug treatment coverage among people who inject drugs in 90 large metropolitan areas in the USA, 1993-2007
P2860
Q28265279-78383A22-0BCC-4B26-841A-D2F19AF38C64Q30378147-9358434B-DC41-45B4-A03B-B2A27F1AFCB0Q30496986-E97631D1-2B88-48AE-AA36-A8F01B5EFBC1Q30751889-EF2E4111-6F2B-44A7-BFB8-06D6C8603B88Q34005620-6B45971D-0B05-4AB8-8DAA-ADD2C80A3279Q34732952-BD7C5BE8-ED94-4521-BAC5-5C31C01224EAQ35088386-43109B65-9591-4E9E-B439-780965337662Q35112836-375A85AE-CA96-4D15-8DC7-8F877416F9B9Q35389163-CD33996A-401A-4909-A762-7C925FF0DBCEQ35618756-71920533-CA44-43CA-BF1B-F0865A706F95Q35686969-9CE27DB6-77B0-43EF-8404-1DC0BF7F842AQ35726267-A90D6F0F-A045-4AF5-BB5C-B6311FB9D276Q35763921-2C71D7FD-477C-49AA-8204-7F60784D10C8Q36248580-3435385C-C3BF-468E-9B6A-5E9D36CB28BAQ36508384-B6B8A3EB-0259-4FE1-BFD2-6FD1F877C1BCQ36793941-BF993B6E-F59C-42A3-8907-834CD368CC39Q36906548-8F567672-0F53-459A-841B-E022D1E4D3B4Q37117229-19FEAD52-C067-41CD-9028-6D4663ABC992Q37163341-59FD8201-2ABA-42B0-A490-45543C0EE7F8Q37227121-364787A8-3828-487C-9B12-77E110B296B6Q37335799-05F502D7-CFCD-4045-9063-79220FEB2702Q37397043-8DC9A6B8-D899-4AB8-A63A-8E6B119DBEC4Q37425629-0A94FA16-1E2F-4F26-89B7-5CEFB3760EE0Q38628748-66FD7E21-775D-423E-B55A-A2F6D257C2C0Q38719086-89C12439-9C7A-472A-B140-C0AE150CE897Q38885762-CD7ED0B7-17AF-439A-A243-7702377B461BQ41441944-D2C1CE2E-DA7F-4171-99FD-D35E5CC4F6CDQ43218767-A4C29F0E-2033-4997-8888-567559E3FE99Q44500239-9BC6D64F-B92A-456D-ACA6-968174103BFBQ49270407-FBEF2C21-5B95-4E97-83DB-9B9F4FCD180EQ57170187-1257A8C9-3BBC-4842-BEE0-6527E2704B84
P2860
The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The potential role of buprenor ...... d in HIV infection prevention.
@ast
The potential role of buprenor ...... d in HIV infection prevention.
@en
type
label
The potential role of buprenor ...... d in HIV infection prevention.
@ast
The potential role of buprenor ...... d in HIV infection prevention.
@en
prefLabel
The potential role of buprenor ...... d in HIV infection prevention.
@ast
The potential role of buprenor ...... d in HIV infection prevention.
@en
P2093
P356
P1476
The potential role of buprenor ...... d in HIV infection prevention.
@en
P2093
Duncan Smith-Rohrberg
Frederick L Altice
Lois Eldred
Lynn E Sullivan
Sharon Stancliff
P304
P356
10.1086/508181
P407
P478
43 Suppl 4
P50
P577
2006-12-01T00:00:00Z